Back to FeedIntel Vault / Permanent Record
[ARCHIVE]2026-08-04T18:00:31.147862+00:00
InfuSystem anticipates 6% to 8% annual revenue growth as wound care expands and adjusted EBITDA margin targets low to mid-20% (NYSE:INFU)

InfuSystem anticipates 6% to 8% annual revenue growth as wound care expands and adjusted EBITDA margin targets low to mid-20% (NYSE:INFU)

Executive Summary

InfuSystem (INFU) Q2 2026 earnings call recap: record $36.9M revenue, GE contract impact, Oncology/Wound Care growth, EBITDA outlook—read now.

Deep analysis unavailable for this source.

View Original SourceClassification: Open